e-cigarette use assoc w/ a 1.5-fold incr risk of RA & SLE. All of Us Research prg matched 15,909 e-cig users vs nonusers. 66 new RA or SLE among current e-cig (IR 1.43/1,000PYs) vs nonusers (0.93/1,000PYs; IRR 1.54); applies to past or current smokers https://t.co/xYRezwQFYC https://t.co/pnNANfui4Y

• https://www.sciencedirect.com/science/article/abs/pii/S0049017226001484

VA study of 4108 RA-ILD (2006-21). PRED use was 65-77%, A& 1st line Rx (MMF, AZA, RTX, CTX) incr after ILD, use was low (1.2-12%). MTX decr (47 to 30%), but LEF, TNFi, ABA incr. Predictors of ILD Rx: FVC, CCP+, ILD Dx after 2012. https://t.co/GT3Vwo11w1 https://t.co/KFDKsjkN0k

• Real‐World Treatment Patterns in Rheumatoid Arthritis–Associated Interstitial L…

20 long-standing PsO pts (freq nai,scalp dz) (b/tsDMARD-naive) Rx w/ OL apremilast 30 bid x 6 mos. Enthesitis (MRI or HR-pQCT) stable, PsAMRIS stable; no new erosions, but PASI (11-->5) & TJC signif improved (3.2-->0.8) https://t.co/UjACvXyvKs https://t.co/xfQGcW0yz7

• Effect of apremilast on entheseal bone damage in psoriasis patients at risk of …

“Math has no opinion” - Mellody Hobson

In the JAMA review of shoulder pain, what is the recommended first-line treatment for most shoulder diagnoses? Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa https://t.co/mKClL2P0Tc

• RheumIQ Weekly Quiz | RheumNow

Retrospective Medicare comparison 450 paired #PMR cohorts Rx w/ IL-6 inhib or csDMARDs. At 1 yr, IL-6i pts (vs csDMARD) had signif more GC D/C (adj HR 1.28) or minimal GC use (<3mg/d) (aHR 1.28). Hosp. infxn 2X higher in IL-6i (12.2 vs 5.7 per 100 PY) in year 1, but not year 2 https://t.co/G4eIusHDPa

Efgartigimod Efficacy in Idiopathic Inflammatory Myopathy Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis). https://t.co/9tgAM8YVh1

SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/DIe2OJhZIc

In rheumatoid arthritis, which RA-specific factor is the strongest modifiable driver of venous thromboembolism risk? Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/L69CPXWqfl

• RheumIQ Weekly Quiz | RheumNow

Misdiagnosis of Still's Disease High fever, strange rashes, scary labs often lead to a consideration of Still's disease (AOSD or systemic JIA). Yet the dramatic onset of a systemic disorder may overlap with another, and possibly as rare, systemic disorder that should not be https://t.co/mCbNBAt9T5

Risk of Venous Thromboembolism in Rheumatoid Arthritis RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; https://t.co/IsS6vqo6vU

Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be >15 million (4.6% US population); 34% have > 1 AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://t.co/tfSCpRqHbY https://t.co/VckjIoGOaa

• Estimation of prevalence of autoimmune diseases in the United States using elec…